Arrowhead Pharmaceuticals reported early trial data showing notable reductions in body, liver, and visceral fat from two experimental obesity drugs, with more results expected in 2026.
Arrowhead (ARWR) announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback